Why Illumina Stock Zoomed Higher on Thursday
A legal opinion on the other side of Planet Earth put some juice into 's (NASDAQ: ILMN) stock on Thursday. The gene-sequencing specialist saw its share price rise by over 3%, against the S 500 index's 0.3% bump, on strong indication that a regulator's move against the company might soon be reversed.
That day, a senior advisor to the European Commission (EC) -- the European Union's (EU) executive arm that also holds certain regulatory powers -- criticized the Commission's ruling on an Illumina acquisition. Specifically, this was the company's $8 billion cash-and-stock deal to purchase cancer detection company Grail, agreed in 2020.
In 2021, the EC blocked the deal following requests from a clutch of EU countries. This, despite the fact that the purchase was under the revenue threshold according to EU regulations. The Commission cited a rarely used power known as Article 22 as the basis for its decision.
Source Fool.com
Illumina Inc. Aktie
Starkes Kaufinteresse bei Illumina Inc., mit einer großen Anzahl an Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 162 € für Illumina Inc. signalisiert eine mögliche Steigerung von über 50% gegenüber 107.38 €.
